Search

Harnessing head and neck cancer genomics for personalised medicine

Luc Morris updates us on the future of cancer diagnosis and treatment, which lies in “personalised oncology”, where specific molecular alterations of each tumour will be identified, and matched with actionable alterations in existing therapies, ushering in the era of...

The doctor – pharmaceutical company relationship

‘Which drug rep is taking us out tonight?’ We have heard this phrase uttered at conferences since meetings began, but as Dylan said ‘those times they are a changing’ thanks to the Association of the British Pharmaceutical Industry (ABPI) and...

2014: Are today’s implantable devices better than conventional solutions for patients with conductive or mixed hearing loss?

Patients with conductive or mixed hearing loss become candidates for amplification when reconstructive surgery is not viable. Three common amplification options are conventional acoustic devices, such as behind-the-ear devices (BTEs), (implantable) bone-conduction devices and active middle ear implants. The goal...

Wireless accessories for hearing aid users: putting the ‘soul’ back into hearing – a case study

The following case study reports on the experiences of a hearing impaired National Health Service (NHS) patient who was given Bluetooth accessories as part of a study into their benefits when used with hearing aids [1]. The name of the...

Building partnerships for person-centred care

The Ida Institute are a renowned organisation that develops tools, materials and resources to help hearing care professionals integrate person-centred care into clinical practice. Lise Lotte Bundesen has been at the helm of this organisation since its inception; in this...

Kuduwave™ testing aboard the ISS

What does it take to make an audiometer and tympanometry ready for the space age? In a recent interview, Jillian Scotland and Dirk Koekemoer shared their first-hand experience of getting the Kuduwave ready for a voyage to the ISS. It...

COOL therapy for cisplatin-induced hearing loss

Cisplatin is a commonly used cancer therapy, with nearly 50% of patients undergoing chemotherapy receiving cisplatin as part of their regimen [1]. Depending on the dose, incidence of hearing loss has been reported as 12-100% in adults, and 37-94% in...

Deaf identity is not cookie cutter shaped: a CI user in a hearing world

Sam Burgess tells us what deaf identity means to her as a service manager in a busy healthcare library, with a cochlear Implant. To begin with, I have been deaf since birth due to congenital rubella. I have not known...